BEVACIZUMABMEDICAL careWe aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion.We calculated costs and quality-adjusted life-years from the UK National ...
Bevacizumab (Avastin, Genentech), on the other hand, was initially approved by the FDA for systemic administration for the treatment of metastatic colorectal cancer. Bevacizumab is a much larger molecule that was thought to be unable to cross the retina effectively, but it does, and it has ...
In comparsion with treatment with the low cost antivascular endothelial growth factor (VEGF) drug bevacizumab (Avastin), the more expensive alternatives aflibercept (Eylea) and ranibizumab (Lucentis) are not cost effective for diabetic macular edema, a new study has found.1 Aflibercept and ...